Format

Send to

Choose Destination
Immunotherapy. 2016 Jun;8(6):693-704. doi: 10.2217/imt-2016-0013.

Checkpoint inhibition for colorectal cancer: progress and possibilities.

Author information

1
School of Medicine, University of North Carolina, Chapel Hill, NC, USA.
2
Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, IN, USA.
3
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.

Abstract

Colorectal cancer (CRC) remains the third most common cause of cancer death in the USA. Despite an increase in the repertoire of treatment options available for CRC, median overall survival has plateaued at approximately 2.5 years. Strategies that engage the patient's native immune system to overcome checkpoint inhibition have proven to be promising in subsets of CRCs, specifically those with mismatch repair deficiency. Further studies are required to determine combinations of standard therapies with immunotherapy drugs and to discover the best biomarkers to predict response. This review provides insight into the progress made in treating patients with advanced CRC with immunotherapeutics and the areas that demand further research to make these drugs more effective in this patient population.

KEYWORDS:

checkpoint inhibition; colorectal cancer; immunotherapy

PMID:
27197538
DOI:
10.2217/imt-2016-0013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center